© 2005 European Society for Medical Oncology
Original article |
Impact of EGFR expression on colorectal cancer patient prognosis and survival
,*1 Département d'Oncologie Médicale, Hôpital Pitié-Salpétrière, Paris; 2 Département d'Anatomopathologie, Hôpital Avicenne, Bobigny; 3 Département de Radiothérapie et Statistique, Hôpital Européen Georges Pompidou, Paris; 4 Département d'Oncopharmacologie, Centre Antoine Lacassagne, Nice; 5 Département de Gastro-Entérologie, Hôpital Avicenne, Bobigny; 6 Département de Chirurgie Viscérale, Hôpital Bobigny, Bobigny; 7 Département d'Oncologie Médicale, 8 Département d'Hématobiologie, 9 Département de Biochimie et de Biologie Moléculaire, Hôpital Avicenne, Bobigny; 10 Département d'Anatomopathologie, Centre Anticancéreux, Clermont-Ferrand, France
* Correspondence to: Dr J.-P. Spano, MD, Hôpital Pitié-Salpetrière, Département d'Oncologie Médicale, 47 Boulevard de l'Hôpital, 75013 Paris, France. Tel: +33-1-42-16-04-52; Fax: +33-1-42-16-04-65; Email: jean-philippe.spano{at}psl.ap-hop-paris.fr
Background: Epidermal growth factor receptor (EGFR) is overexpressed in many types of cancers, especially colorectal cancer (CRC), and seems to reflect more aggressive histological and clinical behaviors. The aim of this study was to evaluate EGFR immunohistochemical reactivity in CRC biopsies, and to analyze its relationship with various histological and clinical characteristics and survival.
Patients and methods: A composite EGFR score, obtained by multiplying the grade (% positive cells) by the intensity of labeling (0–9) was used to define patients with low or high EGFR expression whose clinicopathological features were then compared. Univariate tests and multivariate Cox proportional hazards model were applied for data analysis.
Results: Tissue sections from 150 CRC patients with a median follow-up of 40 months were examined. Median patient age at diagnosis was 70 years (range 38–89 years). EGFR reactivity was positive for 143 patients (97%) and high for 118 (80%). According to multivariate analysis, EGFR overexpression was significantly associated with tumor stage, with a higher percentage of EGFR overexpression in T3 than T4 (P=0.003) and not with overall survival.
Conclusions: EGFR was overexpressed in this CRC patient population and was significantly associated with TNM (tumor–node–metastasis) stage T3. In the context of a new therapeutic strategy using EGFR-targeted therapies, although EGFR remains a controversial prognostic factor, this expression–stage association may play a crucial role in a decision to initiate an adjuvant treatment.
Key words: colorectal carcinoma, EGFR expression, TNM, therapeutic strategy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H Adams, A Tzankov, A Lugli, and I Zlobec New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma J. Clin. Pathol., November 1, 2009; 62(11): 986 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. THEODOROPOULOS, E. KARAFOKA, J. G. PAPAILIOU, P. STAMOPOULOS, C. P. ZAMBIRINIS, K. BRAMIS, S.-G. PANOUSSOPOULOS, E. LEANDROS, and J. BRAMIS p53 and EGFR Expression in Colorectal Cancer: A Reappraisal of 'Old' Tissue Markers in Patients with Long Follow-up Anticancer Res, February 1, 2009; 29(2): 785 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Zlobec and A Lugli Prognostic and predictive factors in colorectal cancer Postgrad. Med. J., August 1, 2008; 84(994): 403 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I Zlobec and A Lugli Prognostic and predictive factors in colorectal cancer J. Clin. Pathol., May 1, 2008; 61(5): 561 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Zlobec, R. Steele, L. Terracciano, J. R Jass, and A. Lugli Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer J. Clin. Pathol., October 1, 2007; 60(10): 1112 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Thieblemont and B. Coiffier Lymphoma in Older Patients J. Clin. Oncol., May 10, 2007; 25(14): 1916 - 1923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Spano and G. Milano Reply to the "Letter to the Editor on 'Relevance of EGFR expression in colorectal cancer'" by C. Alliot (Ann Oncol 2005; 16: 1557) Ann. Onc., September 1, 2005; 16(9): 1558 - 1559. [Full Text] [PDF]
|
|
|
|
|
|
C. Alliot Relevance of EGFR expression in colorectal cancer Ann. Onc., September 1, 2005; 16(9): 1557 - 1558. [Full Text] [PDF]
|
|
|
|
|
|
L. Repetto, W. Gianni, A. M. Agliano, and P. Gazzaniga Impact of EGFR expression on colorectal cancer patient prognosis and survival: a response Ann. Onc., September 1, 2005; 16(9): 1557 - 1557. [Full Text] [PDF]
|
|
|
|
|
|
J. P. Spano, R. Fagard, J.-C. Soria, O. Rixe, D. Khayat, and G. Milano Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives Ann. Onc., February 1, 2005; 16(2): 189 - 194. [Abstract] [Full Text] [PDF]
|
|